
CMA Accuses Merck of Restricting Access to Remicade Biosimilars in UK
The Competition and Market’s Authority is accusing Merck Sharp & Dohme of offering a discount for Remicade that may have restricted the sale of biosimilar competition in the UK.
The United Kingdom’s Competition and Markets Authority (CMA) is accusing Merck Sharp & Dohme Limited (MSD) of operating an “anti-competitive discount scheme” for its inflammatory disease medication Remicade (infliximab), CMA said in a May 23, 2017
An individual with knowledge of the case
In a
According to Merck’s
Source: CMA, MSD, Reuters
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.